Back to All Resources

Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia

October 16, 2023

10th International MDM2 Workshop

Kymera MDM2 Workshop October 2023 Picture
View Poster
Area of Focus
Oncology
Programs
MDM2 (KT-253)
Indications
Liquid Tumors Solid Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

June 6, 2023
Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors
European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
View Resource
December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
View Resource